Blood purification · 2025
Phoxilium® as a Phosphate-Sparing Solution for Continuous Renal Replacement Therapy in Paracetamol-Induced Acute Liver Failure.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Gabriel, Fisher Caleb, Baldwin Ian C, Warrillow Stephen Joseph, Chaba Anis, Bellomo Rinaldo, Serpa Neto Ary
Аннотация
INTRODUCTION: Hypophosphataemia is common in acute liver failure (ALF) and may worsen during continuous renal replacement therapy (CRRT) with phosphate-free fluids. We aimed to evaluate the safety and efficacy of Phoxilium®, a phosphate-containing CRRT fluid.
METHODS: We conducted a retrospective single-center cohort study of paracetamol-induced ALF patients treated with CRRT between January 2018 and May 2024 as our ICU transitioned from Accusol® to Phoxilium®. We obtained data on demographics, biochemistry, and outcomes. We compared biochemical variables every 6 h up to 48 h post-CRRT initiation and then every 12 h until 168 h. The primary outcome was the occurrence of severe hypophosphataemia (<0.32 mmol/L).
RESULTS: In 38 ALF patients (Phoxilium® = 14 and Accusol® = 24), Phoxilium® was associated with a reduction in the incidence of severe hypophosphataemia (0% vs. 38%; p = 0.014), a reduction in its median burden (proportion of phosphate readings <0.81 mmol/L: 13% [interquartile range: 2-33%] vs. 44% [29-51%]; p = 0.001), and significantly lower phosphate supplementation requirements (median, 45 mmol [20-70 mmol] vs. 100 mmol [60-210 mmol]; p = 0.008). Phoxilium® patients experienced a small but significant decrease in median arterial pH and standard base excess, which remained within normal limits, but lower than with Accusol® (p = 0.018 and p = 0.046, respectively). No significant differences were observed in clinical outcomes.
CONCLUSION: In paracetamol-induced ALF patients, Phoxilium® was associated with reduced incidence of severe hypophosphataemia, hypophosphataemia burden, and need of phosphate supplementation. Larger studies are needed to further assess its impact on ALF patient outcomes.
METHODS: We conducted a retrospective single-center cohort study of paracetamol-induced ALF patients treated with CRRT between January 2018 and May 2024 as our ICU transitioned from Accusol® to Phoxilium®. We obtained data on demographics, biochemistry, and outcomes. We compared biochemical variables every 6 h up to 48 h post-CRRT initiation and then every 12 h until 168 h. The primary outcome was the occurrence of severe hypophosphataemia (<0.32 mmol/L).
RESULTS: In 38 ALF patients (Phoxilium® = 14 and Accusol® = 24), Phoxilium® was associated with a reduction in the incidence of severe hypophosphataemia (0% vs. 38%; p = 0.014), a reduction in its median burden (proportion of phosphate readings <0.81 mmol/L: 13% [interquartile range: 2-33%] vs. 44% [29-51%]; p = 0.001), and significantly lower phosphate supplementation requirements (median, 45 mmol [20-70 mmol] vs. 100 mmol [60-210 mmol]; p = 0.008). Phoxilium® patients experienced a small but significant decrease in median arterial pH and standard base excess, which remained within normal limits, but lower than with Accusol® (p = 0.018 and p = 0.046, respectively). No significant differences were observed in clinical outcomes.
CONCLUSION: In paracetamol-induced ALF patients, Phoxilium® was associated with reduced incidence of severe hypophosphataemia, hypophosphataemia burden, and need of phosphate supplementation. Larger studies are needed to further assess its impact on ALF patient outcomes.